Ind-Swift Laboratories Reports Preferential Warrant Proceeds Utilization for Q2FY27
Ind-Swift Laboratories Ltd 路 Others (Uncategorized) 路 03 Nov 2026, 8:26 pm
Ind-Swift Laboratories Reports Preferential Warrant Proceeds Utilization for Q2FY27 CARE Ratings issued its Monitoring Agency Report for Ind-Swift Laboratories regarding its Rs 137.20 crore preferential warrant issue allotted on 17th Sep'26. As of 30th Sep'26, the company raised Rs 34.30 crore, utilizing Rs 15.60 crore and leaving Rs 18.70 crore unutilized in ICICI Bank fixed deposits. Deployments included Rs 6.315 crore for facility expansion, Rs 4.853 crore in Dubai subsidiary ISLL Middle East, Rs 3.989 crore for working capital, Rs 0.335 crore for R&D, and Rs 0.108 crore for GCP. CARE noted zero material deviations.
Original exchange filing (PDF)
More announcements from Ind-Swift Laboratories Ltd
- Please find enclosed transcript for earnings call held on November 04, 2026. 路 10 Nov 2026
- Audio recording of earning conference call held on 04.11.2026 on un-audited financial results for the quarter ended 30.09.2026. 路 05 Nov 2026
- Please find enclosed investor presentation on un-audited financial results for the quarter ended September 30, 2026 路 04 Nov 2026
- Monitoring Agency Report for the quarter ended September 30, 2026 in respect of funds raised through Preferential Issue 2.6 Cr Fully Convertible Warrants 路 03 Nov 2026
- Please find enclosed Schedule of Analyst / Investor Meet which will be held on Wednesday, November 04, 2026, at 04.00 P.M. IST in respect of financial results of the Company for the quarter .... 路 04 Nov 2026
- Press Release in respect of Unaudited Financial Results (Standalone & Consolidated) for the second quarter and half year ended September 30, 2026 路 30 Oct 2026
- Please refer attached pdf 路 30 Oct 2026
- Please refer attached pdf 路 30 Oct 2026
